Treatment of Hodgkin's disease: the role of radio- and/or chemotherapy in advanced stages.
In recent years, anthracycline-containing single, alternating or "hybrid' combination chemotherapy regimens have achieved superior results in the treatment of patients with advanced Hodgkin's disease to those with single regimens of the MOPP type. A number of studies also suggest the superiority of combined modality regimens with chemotherapy and radiation therapy to chemotherapy alone among this group of patients. These studies and recent analyses of prognostic factors among patients treated with these current treatment approaches have been the subjects of this brief review.
Straus
D J
DJ
Memorial Sloan Kettering Cancer Center, NY 10021, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy* / Q000628:therapy; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone